The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis

Affiliations

¹ Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency (EMA), Amsterdam, The Netherlands.
² International Affairs Division, European Medicines Agency (EMA), Amsterdam, The Netherlands.
³ Clinical Pharmacology Unit, University of Kinshasa, Democratic Republic of the Congo.
⁴ Uganda National Drug Authority, Kampala, Uganda.
⁵ Medicines Evaluation Department, National Authority of Medicines and Health Products (INFARMED), Lisbon, Portugal.
⁶ Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), London, United Kingdom.

Eric Pelfrene et al. PLoS Negl Trop Dis. 2019.

. 2019 Jun 27;13(6):e0007381.

doi: 10.1371/journal.pntd.0007381. eCollection 2019 Jun.

¹ Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency (EMA), Amsterdam, The Netherlands.
² International Affairs Division, European Medicines Agency (EMA), Amsterdam, The Netherlands.
³ Clinical Pharmacology Unit, University of Kinshasa, Democratic Republic of the Congo.
⁴ Uganda National Drug Authority, Kampala, Uganda.
⁵ Medicines Evaluation Department, National Authority of Medicines and Health Products (INFARMED), Lisbon, Portugal.
⁶ Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), London, United Kingdom.

No abstract available

Conflict of interest statement

The authors have declared that no competing interests exist.

1. Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet 2017; 390: 2397–2409. 10.1016/S0140-6736(17)31510-6 - DOI - PubMed
1. European Medicines Agency. Medicines for use outside the European Union; 2018. Database: EMA; Available from: https://www.ema.europa.eu/human-regulatory/marketing-authorisation/medic.... [cited 2018 Nov 27].
1. Kande Betu Ku Mesu V, Mutombo Kalonji W, Bardonneau C, Valverde Mordt O, Blesson S, Simon F, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 2018; 391: 144–154. 10.1016/S0140-6736(17)32758-7 - DOI - PubMed
1. Chappuis F. Oral fexinidazole for human African trypanosomiasis. Lancet 2018; 391: 100–102. 10.1016/S0140-6736(18)30019-9 - DOI - PubMed
1. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97(1): 55–64. 10.1016/j.actatropica.2005.08.001 - DOI - PubMed